U.S. Markets close in 5 hrs 52 mins
  • S&P 500

    4,080.48
    +0.37 (+0.01%)
     
  • Dow 30

    34,360.74
    -229.03 (-0.66%)
     
  • Nasdaq

    11,487.62
    +19.62 (+0.17%)
     
  • Russell 2000

    1,893.94
    +7.36 (+0.39%)
     
  • Crude Oil

    82.82
    +2.27 (+2.82%)
     
  • Gold

    1,816.50
    +56.60 (+3.22%)
     
  • Silver

    22.86
    +1.08 (+4.98%)
     
  • EUR/USD

    1.0530
    +0.0122 (+1.1688%)
     
  • 10-Yr Bond

    3.6150
    -0.0880 (-2.38%)
     
  • Vix

    20.30
    -0.28 (-1.36%)
     
  • GBP/USD

    1.2289
    +0.0227 (+1.8839%)
     
  • USD/JPY

    135.5840
    -2.4960 (-1.8076%)
     
  • BTC-USD

    17,095.27
    +261.25 (+1.55%)
     
  • CMC Crypto 200

    404.66
    -1.49 (-0.37%)
     
  • FTSE 100

    7,573.94
    +0.89 (+0.01%)
     
  • Nikkei 225

    28,226.08
    +257.09 (+0.92%)
     

Why Editas Medicine Was Winning on Wednesday

Shares of Editas Medicine (NASDAQ: EDIT) were rocketing more than 13% higher in late-afternoon trading on Wednesday, and it was little wonder. The company scored twin beats in its latest set of quarterly results, with one line item in particular being a standout. The genome editing company's revenue was $6.3 million.